A distinct pharmacokinetic profile1
Single-Day, Crossover Pharmacokinetic Study: Mean Cyclobenzaprine Concentration Over Time (N=36)3
- AMRIX provides early systemic exposure of cyclobenzaprine followed by consistent plasma levels1
- AMRIX reduces fluctuations in plasma levels seen with cyclobenzaprine immediate release (IR) 10 mg 3 times daily3
- Overall systemic exposure of AMRIX 30 mg was similar to that of cyclobenzaprine IR 10 mg 3 times daily3
AMRIX is contraindicated in patients who are hypersensitive to any of its
components.
AMRIX is contraindicated with concomitant use of monoamine
oxidase (MAO) inhibitors or within 14 days after their discontinuation.
AMRIX
may have life-threatening interactions with MAO inhibitors.
AMRIX is contraindicated
during the acute recovery phase of myocardial infarction; in patients with
arrhythmias, heart block conduction disturbances, or congestive heart failure; or
in patients with hyperthyroidism.
AMRIX may enhance the effects of alcohol,
barbiturates, and other CNS depressants.
AMRIX should not be used in elderly patients
or in patients with impaired hepatic function.
Click here for additional important safety information.